|
Monday, March 26 — 1:00 PM — CC 5 A/B
Click on the blue numbers in parentheses to display abstracts.
Click the  button next to any title to add to Itinerary Planner...
...then notice the 'Event Added' prompt
in the toolbar above as feedback: | |  |
|
Section D - BREAST PATHOLOGY
Chaired by: Jean Simpson and Sandra Shin
| Time | Title and Authors | Itinerary
Planner |
| 1:00 |
Extremely High Concordance between Immunohistochemistry and FISH Testing for HER2 Status Using Subtraction Methodology Scoring in Breast Cancer: A Study of 5942 Cases
(154)
AM Gown, LC Goldstein, TS Barry, SJ Kussick, PL Kandalaft, PM Kim PhenoPath Laboratories and IMPRIS, Seattle, WA
|  Add |
| 1:15 |
Expression of a Novel Cell-Cycle Regulated Protein HTF9C, Identifies a Subgroup of HER2 Positive Breast Cancer with a More Aggressive Clinical Course
(109)
DC Dim, DG Hicks, BJ Yoder, RR Tubbs, TG Budd, BZ Ring, RA Beck, NC Estopinal, RS Seitz, DT Ross Roswell Park Cancer Institute, Buffalo, NY; MicroPath Labs, Lakeland, FL; Cleveland Clinic Foundation, Cleveland, OH; Applied Genomic Inc, Burlingame, CA; Comprehensive Institute of Huntsville, Huntsville, AL
| Add |
| 1:30 |
Comparison of Oncotype-DX Recurrence Score and Standard Immunohistochemical Prognostic Markers
(131)
MC Grimes, J Coad, BJ Oliverio, KJ Bloom CLARiENT Inc, Aliso Viejo, CA; West Virginia University, Morgantown, WV
| Add |
| 1:45 |
Neuregulin Expression Modulates Clinical Response to Herceptin in Patients with Metastatic Breast Cancer (MBC)
(107)
E de Alava, M Abad, A Ocaña, CA Rodríguez, JC Montero, JJ Cruz, A Pandiella Centro de Investigación del Cáncer/Hospital Universitario de Salamanca, Salamanca, Spain
| Add |
| 2:00 |
MYC Amplification in Breast Cancer: A Chromogenic In Situ Hybridisation Study
(198)
SM Rodriguez Pinilla, RL Jones, MB Lambros, E Arriola, K Savage, M James, SE Pinder, JS Reis-Filho ICR, London, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| Add |
| 2:15 |
Expression of Estrogen Receptor Co-Activator AIB1 in Breast Cancer
(169)
A Morimiya, D Turbin, D Hunstman, Q Zhang, M Jeng, H Nakshatri, S Badve Indiana University, Indianapolis, IN; University of British Columbia, Vancouver, BC, Canada
| Add |
| 2:30 |
The Molecular Classification System Is Useful for Determining the Likelihood of Complete Pathologic Response to Neoadjuvant Chemotherapy in Locally Advance Breast Cancer
(232)
M Young, NS Goldstein William Beaumont Hospital, Royal Oak, MI
| Add |
| 2:45 |
Discordant Gross and Microscopic Pathology Following Neoadjuvant Treatment of Breast Cancer: Implications for Evaluating Tumor Size and Margin Status
(189)
JT Rabban, YY Chen University of California, San Francisco, San Francisco, CA
| Add |
| 3:00 |
RECESS, EXHIBITS, POSTER SESSION II
Coffee Break sponsored by US Labs
| |
| 4:30 |
NATHAN KAUFMAN TIMELY TOPICS LECTURE
Steven L. Kunkel, Ph.D.
Inflammatory Keys to Chronic Disease
Convention Center Room 6 A/B/C/F
| Add |
|
|
